Hatos A et al (2019) DisProt: intrinsic protein disorder annotation in 2020
Bottom Line: What to Know Before Starting With altRx altRx is a self-pay GLP-1 telehealth platform that, according to its own published source materials, operates a clearly disclosed three-entity model: altRx as the technology and marketing platform, independent medical groups as the clinical decision-makers, and partner pharmacies described by altRx as USA-certified as the medication dispensers
Personalized options aligned with your health and wellness goals
1 Treatment groups Experimental Treatment Semaglutide Pen Injector 1.0 mg weekly Once weekly subcutaneous injection Other Name: Wegovy Semaglutide is already approved in European Union, United States, Canada, Japan for the following indications: Type 2 diabetes Cardiovascular disease Obesity Type 2 diabetes Cardiovascular disease Obesity Type 2 diabetes Cardiovascular disease Obesity Type 2 diabetes Cardiovascular disease Obesity Obesity Type 2 diabetes Find a Clinic Near You Who Is Running the Clinical Trial
Side Effects : In addition to the shared GLP-1 side effects above, increased heart rate, low blood sugar (especially in people with diabetes), and injection site reactions may also occur